-
2
-
-
0035748137
-
Hepatitis C and hepatocellular carcinoma
-
Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options Oncol. 2001;2:473–483.
-
(2001)
Curr Treat Options Oncol
, vol.2
, pp. 473-483
-
-
Yao, F.1
Terrault, N.2
-
3
-
-
84872119847
-
Update in liver transplantation
-
Alqahtani SA. Update in liver transplantation. Discov Med. 2012;14:133–141.
-
(2012)
Discov Med
, vol.14
, pp. 133-141
-
-
Alqahtani, S.A.1
-
5
-
-
46349089961
-
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
-
Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–287.
-
(2008)
J Hepatol
, vol.49
, pp. 274-287
-
-
Berenguer, M.1
-
6
-
-
33745343818
-
Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis
-
Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–1599.
-
(2006)
Am J Transplant
, vol.6
, pp. 1586-1599
-
-
Wang, C.S.1
Ko, H.H.2
Yoshida, E.M.3
Marra, C.A.4
Richardson, K.5
-
7
-
-
84919686294
-
Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals
-
Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. Liver Int. 2015;35(Suppl 1):44–50.
-
(2015)
Liver Int
, vol.35
, pp. 44-50
-
-
Coilly, A.1
Roche, B.2
Duclos-Vallée, J.C.3
Samuel, D.4
-
8
-
-
84899008211
-
Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity
-
Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity.” Am J Transplant. 2014;14:994–1002.
-
(2014)
Am J Transplant
, vol.14
, pp. 994-1002
-
-
Gane, E.J.1
Agarwal, K.2
-
10
-
-
84938739029
-
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting
-
Beinhardt S, Peck-Radosavljevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Transpl Int. 2015;28:1011–1024.
-
(2015)
Transpl Int
, vol.28
, pp. 1011-1024
-
-
Beinhardt, S.1
Peck-Radosavljevic, M.2
Hofer, H.3
Ferenci, P.4
-
11
-
-
84911409020
-
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
-
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
-
(2014)
Lancet
, vol.384
, pp. 1756-1765
-
-
Lawitz, E.1
Sulkowski, M.S.2
Ghalib, R.3
-
12
-
-
84892619580
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
-
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
-
(2014)
N Engl J Med
, vol.370
, pp. 211-221
-
-
Sulkowski, M.S.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
-
13
-
-
84930034351
-
Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients
-
Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823–830.
-
(2015)
Liver Transpl
, vol.21
, pp. 823-830
-
-
Gutierrez, J.A.1
Carrion, A.F.2
Avalos, D.3
-
14
-
-
84945442148
-
Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients
-
Saab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35:2442–2447.
-
(2015)
Liver Int
, vol.35
, pp. 2442-2447
-
-
Saab, S.1
Greenberg, A.2
Li, E.3
-
15
-
-
84920941109
-
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late
-
Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923–927.
-
(2014)
Dig Liver Dis
, vol.46
, pp. 923-927
-
-
Pellicelli, A.M.1
Montalbano, M.2
Lionetti, R.3
-
16
-
-
84878475234
-
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C
-
Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601–1605.
-
(2013)
Am J Transplant
, vol.13
, pp. 1601-1605
-
-
Fontana, R.J.1
Hughes, E.A.2
Bifano, M.3
-
17
-
-
84961886745
-
Direct acting antiviral therapy after liver transplantation
-
Kwo PY. Direct acting antiviral therapy after liver transplantation. Curr Opin Gastroenterol. 2016;32:152–158.
-
(2016)
Curr Opin Gastroenterol
, vol.32
, pp. 152-158
-
-
Kwo, P.Y.1
-
18
-
-
68249119265
-
Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity
-
Stockmann M, Lock JF, Riecke B, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250:119–125.
-
(2009)
Ann Surg
, vol.250
, pp. 119-125
-
-
Stockmann, M.1
Lock, J.F.2
Riecke, B.3
-
19
-
-
84925033610
-
Reliable assessment of liver function using LiMAx
-
Jara M, Bednarsch J, Valle E, et al. Reliable assessment of liver function using LiMAx. J Surg Res. 2015;93:184–189.
-
(2015)
J Surg Res
, vol.93
, pp. 184-189
-
-
Jara, M.1
Bednarsch, J.2
Valle, E.3
-
21
-
-
84922318694
-
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
-
Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–16.
-
(2015)
Antiviral Res
, vol.116
, pp. 10-16
-
-
Sarrazin, C.1
Lathouwers, E.2
Peeters, M.3
-
22
-
-
84901217985
-
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial
-
Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669–1679.
-
(2014)
Gastroenterology
, vol.146
, pp. 1669-1679
-
-
Forns, X.1
Lawitz, E.2
Zeuzem, S.3
-
23
-
-
33847007641
-
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy)
-
Bahra M, Neumann UP, Jacob D, et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation. 2007;83:351–353.
-
(2007)
Transplantation
, vol.83
, pp. 351-353
-
-
Bahra, M.1
Neumann, U.P.2
Jacob, D.3
-
24
-
-
84983573872
-
Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation
-
Kawaoka T, Takahashi S, Kawakami Y, et al. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. Hepatol Res. 2015;45:1047–1054.
-
(2015)
Hepatol Res
, vol.45
, pp. 1047-1054
-
-
Kawaoka, T.1
Takahashi, S.2
Kawakami, Y.3
-
25
-
-
84871272411
-
Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients
-
Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transpl Int. 2013;26:42–49.
-
(2013)
Transpl Int
, vol.26
, pp. 42-49
-
-
Tanaka, T.1
Selzner, N.2
Therapondos, G.3
Renner, E.L.4
Lilly, L.B.5
-
26
-
-
0242708704
-
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection
-
Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003;9:1159–1165.
-
(2003)
Liver Transpl
, vol.9
, pp. 1159-1165
-
-
Kugelmas, M.1
Osgood, M.J.2
Trotter, J.F.3
-
27
-
-
0026662551
-
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
-
Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753–761.
-
(1992)
Drug Metab Dispos
, vol.20
, pp. 753-761
-
-
Sattler, M.1
Guengerich, F.P.2
Yun, C.H.3
Christians, U.4
Sewing, K.F.5
-
29
-
-
79958708777
-
Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week
-
Lock JF, Malinowski M, Schwabauer E, et al. Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week. Clin Transplant. 2011;25:436–443.
-
(2011)
Clin Transplant
, vol.25
, pp. 436-443
-
-
Lock, J.F.1
Malinowski, M.2
Schwabauer, E.3
-
30
-
-
84930578857
-
Drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients
-
Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients. Ann Pharmacother. 2015;49:674–687.
-
(2015)
Ann Pharmacother
, vol.49
, pp. 674-687
-
-
Burgess, S.1
Partovi, N.2
Yoshida, E.M.3
Erb, S.R.4
Azalgara, V.M.5
Hussaini, T.6
-
31
-
-
77956328248
-
How to define initial poor graft function after liver transplantation? A new functional definition by the LiMAx test
-
Stockmann M, Lock JF, Malinowski M, et al. How to define initial poor graft function after liver transplantation? A new functional definition by the LiMAx test. Transpl Int. 2010;23:1023–1032.
-
(2010)
Transpl Int
, vol.23
, pp. 1023-1032
-
-
Stockmann, M.1
Lock, J.F.2
Malinowski, M.3
-
32
-
-
84925033610
-
Reliable assessment of liver function using LiMAx
-
Jara M, Bednarsch J, Valle E, et al. Reliable assessment of liver function using LiMAx. J Surg Res. 2015;193:184–189.
-
(2015)
J Surg Res
, vol.193
, pp. 184-189
-
-
Jara, M.1
Bednarsch, J.2
Valle, E.3
-
33
-
-
84919587847
-
Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test
-
Malinowski M, Jara M, Lüttgert K, et al. Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test. Dig Dis Sci. 2014;59:2983–2991.
-
(2014)
Dig Dis Sci
, vol.59
, pp. 2983-2991
-
-
Malinowski, M.1
Jara, M.2
Lüttgert, K.3
|